A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AG-181 in Healthy Participants
Latest Information Update: 01 Jul 2025
At a glance
- Drugs AG 181 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Agios Pharmaceuticals
Most Recent Events
- 25 Jun 2025 Planned End Date changed from 1 Jun 2025 to 1 Oct 2025.
- 25 Jun 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Oct 2025.
- 29 May 2025 Planned number of patients changed from 120 to 112.